摘要
尽管肾素-血管紧张素-醛固酮系统(RAAS)阻断剂被认为是Alport综合征(AS)的首要推荐药物已近十年,但始终缺乏对其全面而系统性的疗效评估。自2020年来,多项队列研究展现了RAAS阻断剂延缓AS患者疾病进展的有利证据。近期发表在《Nephrology Dialysis Transplantation》上的一项系统综述与荟萃分析研究汇总了现有对照研究中的所有可用数据,首次系统性地评估了RAAS阻断剂治疗AS的长期效果,为指导AS临床实践决策及《Alport综合征诊治专家共识(2023版)》提供了循证依据和数据支持。
Though renin-angiotensin-aldosterone system(RAAS)blockers have been considered the primary treatment for patients with Alport syndrome(AS)for a decade,there is no comprehensive review with evidence-based analysis evaluating the effectiveness of RAAS blockers in AS.Since 2020,several cohort studies have shown some positive effects of RAAS blockers on improving renal outcomes in patients with AS.A newly published systematic review and meta-analysis summarized all available data from comparative studies and systematically evaluated the effectiveness of RAAS blockers in AS for the first time,which provided data support for improving decisions about the clinical practice of AS.
作者
曾梦遥
狄泓伶
梁菊
刘志红
ZENG Mengyao;DI Hongling;LIANG Ju;LIU Zhihong(National Clinical Research Center for Kidney Diseases,Jinling Hospital,Nanjing 210016,China)
出处
《肾脏病与透析肾移植杂志》
CAS
CSCD
北大核心
2023年第5期455-459,共5页
Chinese Journal of Nephrology,Dialysis & Transplantation
基金
国家自然科学基金专项项目(32141004)。
